Spectrum Pharmaceuticals Launches a Broad-based FUSILEV® Marketing Campaign; Increases Sales Force Footprint
- FUSILEV campaign is expected to further increase awareness of the immediate and long-term clinical value proposition that FUSILEV provides health care professionals treating Colorectal Cancer
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (SPPI), a biotechnology company with a primary focus in oncology and hematology, today announced the launch of the Companys broad-based FUSILEV (levoleucovorin) marketing campaign directed towards oncologists, nurses, office practice managers and pharmacists. The recently launched campaign features a new FUSILEV.com website, health care professional educational tools and resources, digital and online campaign, and peer-to-peer live educational programs.
In conjunction with the launch of this new marketing campaign, and in an effort to further increase our market penetration, Spectrum has made the strategic decision to dedicate additional existing sales resources to FUSILEV. Augmenting the Companys dedicated FUSILEV sales force, all ZEVALIN® (ibritumomab tiuxetan) Injection for Intravenous Use representatives will now also promote FUSILEV. This strategy will leverage all existing health care professional relationships and effectively increase Spectrums FUSILEV dedicated sales resources by approximately 50% with no significant increase in operating expenses.
Physicians continue to increasingly use FUSILEV because of its purity, clinical profile, and supply reliability, said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. Strong commercial support for FUSILEV has been rewarded by increased market penetration and sustained customer loyalty. We believe this campaign will continue to raise awareness of the FUSILEV brand as well as grow the folate analog market.
About FUSILEV® (levoleucovorin)
FUSILEV, a folate analog, is approved as a ready-to-use solution (FUSILEV Injection), and as a freeze-dried powder (FUSILEV for Injection). FUSILEV is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. FUSILEV is also indicated for rescue after high-dose methotrexate therapy in osteosarcoma. FUSILEV is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. FUSILEV, under various trade names, is marketed outside the United States by Pfizer, Sanofi-Aventis, and Takeda.
Important FUSILEV® (levoleucovorin) Safety Considerations
FUSILEV is dosed at one-half the usual dose of racemic d,l-leucovorin. FUSILEV is contraindicated for patients who have had previous allergic reactions attributed to folic acid or folinic acid. Due to calcium content, no more than 16-mL (160-mg) of levoleucovorin solution should be injected intravenously per minute. FUSILEV enhances the toxicity of fluorouracil. Concomitant use of d,l-leucovorin with trimethoprim-sulfamethoxazole for pneumocystis carinii pneumonia in HIV patients was associated with increased rates of treatment failure in a placebo-controlled study. Allergic reactions were reported in patients receiving FUSILEV. Vomiting (38%), stomatitis (38%) and nausea (19%) were reported in patients receiving FUSILEV as rescue after high-dose methotrexate therapy. The most common adverse reactions (> 50%) in patients with advanced colorectal cancer receiving FUSILEV in combination with 5-fluorouracil were diarrhea, nausea and stomatitis. FUSILEV may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible patients.
Full prescribing information can be found at www.FUSILEV.com.
About Colorectal Cancer
According to the National Cancer Institute, Colorectal Cancer is the third most commonly diagnosed cancer in the US. There were about 141,210 new cases of Colorectal Cancer diagnosed in 2011, almost 400 per day. 1,110,000 people are currently living with colorectal cancer in the US and 49,380 deaths were estimated in 2011, almost 136 per day.1
1SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum currently markets two oncology drugs FUSILEV® (levoleucovorin) for Injection in the U.S. and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.®, ZEVALIN®, and FUSILEV® are registered trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE" and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
© 2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
Shiv Kapoor, 702-835-6300
Vice President, Strategic Planning & Investor Relations
Source: Spectrum Pharmaceuticals, Inc.Copyright Business Wire 2012